Related Experiment Video
Updated: Jun 10, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy
Joshua D Mitchell1, Kevin M Alexander2, Hanh Dung Dao3
1Amyloid Center of Excellence, Cardiovascular Division Washington University School of Medicine St. Louis MO USA.
Insights
The prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) has significantly increased, with higher rates in Black patients and the Northeast. Geographic disparities in diagnosis persist despite increased awareness.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Amyloidosis
Background:
- Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, life-threatening restrictive cardiomyopathy.
- Access to specialized care may influence ATTR-CM diagnosis.
- Geographic distribution of resources impacts patient outcomes.
Purpose of the Study:
- To analyze diagnostic trends and geographic disparities in ATTR-CM.
- To assess the distribution of cardiology providers and amyloid centers.
- To identify factors influencing ATTR-CM diagnosis across the US.
Main Methods:
- Cross-sectional geospatial analysis of healthcare resources.
- Retrospective cohort analysis of ATTR-CM patients (July 2016-June 2024).
- Utilized the Komodo Healthcare Map for data.
Main Results:
- ATTR-CM prevalence increased 4-fold; highest in Black patients and the Northeast.
- Mean distance to cardiology: 4.3 miles; to amyloid center: 48.5 miles.
- Significant geographic disparities noted, especially in the Midwest.
Conclusions:
- ATTR-CM prevalence has risen substantially with racial and geographic disparities.
- Strategies are needed to address regional inequities in ATTR-CM diagnosis and care.
- Further research into access to care is warranted.
Background:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, life-threatening form of restrictive cardiomyopathy. Access to cardiology providers and specialized amyloid centers may impact ATTR-CM diagnosis. We sought to elucidate diagnostic disparities of ATTR-CM through assessment of diagnostic trends and the geographic distribution of amyloid centers and cardiology providers in the United States.
Methods:
This was a cross-sectional geospatial analysis of amyloid centers and cardiology providers and a retrospective cohort analysis of patients with ATTR-CM from the Komodo Healthcare Map from July 1, 2016, to June 30, 2024.
Results:
Among 14 980 patients, mean age was 74.8 years, 62.3% were men, 54.1% were White individuals, and 28.8% were Black individuals. The diagnosed prevalence of ATTR-CM was 35.68 per 100 000 persons. Prevalence was highest in Black patients (102.17) and in the Northeast (52.63), and it increased 4-fold over the study period. Mean distance of patients to a cardiology provider was 4.3 miles and to an amyloid center was 48.5 miles. Large areas of the country, particularly in the Midwest, were identified with limited cardiology providers and amyloid centers.
Conclusions:
The prevalence of ATTR-CM has increased substantially since 2017, with notable racial differences; however, there remain geographic disparities. Strategies to address these regional disparities need to be identified.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy V: Interprofessional Care
